Company intelligence / Profile preview
Veradermics
New Haven, Connecticut, United Statesveradermics.com ↗
- Ownership
- Public · MANE
- Development stage
- Other
01
Overview
Veradermics has initiated a pivotal Phase 2/3 clinical trial for VDPHL01 for androgenetic alopecia (pattern hair loss). The company plans to report topline data from Phase 2 studies of VDPHL01 in the first half of 2025. They have also dosed the first patient in a Phase 2 clinical trial for VDMN, an immunostimulatory dissolvable microarray patch containing Candida Antigen Extract for common warts treatment[3][5].
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Oral medicationsdissolvable microarray patchantiviral therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Financials
- Market cap
- $5.4B
- Total revenue
- $0
- Enterprise value
- $4.6B
Beyond the preview
Go deeper on Veradermics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Veradermics.